BACKGROUND: This study documents the direct medical costs associated with treating oral and pharyngeal squamous cell carcinoma (OSCC) as early- or late-stage disease according to the current standard of care. METHODS: This retrospective analysis of California Medicaid claims data calculated direct payments for patients diagnosed with OSCC. Patients were defined as being treated for early- or late-stage disease based on treatment modality. Regression determined significant predictors of year-1 cost of care following diagnosis. RESULTS: Median year-1 cost of care following initial diagnosis was $25,319 for the 229 patients identified. Regression results determined that treatment modality and medical comorbidities were significant in predicting costs (p < .05). Costs for patients treated as having early-stage OSCC were approximately 36% less than for those treated as having late-stage disease (p = .002). CONCLUSION: Treatment for OSCC is a significant cost from Medicaid's perspective, and these data suggest early detection may ease its economic burden.
BACKGROUND: This study documents the direct medical costs associated with treating oral and pharyngeal squamous cell carcinoma (OSCC) as early- or late-stage disease according to the current standard of care. METHODS: This retrospective analysis of California Medicaid claims data calculated direct payments for patients diagnosed with OSCC. Patients were defined as being treated for early- or late-stage disease based on treatment modality. Regression determined significant predictors of year-1 cost of care following diagnosis. RESULTS: Median year-1 cost of care following initial diagnosis was $25,319 for the 229 patients identified. Regression results determined that treatment modality and medical comorbidities were significant in predicting costs (p < .05). Costs for patients treated as having early-stage OSCC were approximately 36% less than for those treated as having late-stage disease (p = .002). CONCLUSION: Treatment for OSCC is a significant cost from Medicaid's perspective, and these data suggest early detection may ease its economic burden.
Authors: David R Lairson; Chi-Fang Wu; Wenyaw Chan; Kristina R Dahlstrom; Samantha Tam; Erich M Sturgis Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-08-24 Impact factor: 4.254
Authors: Carol M Lewis; Gregory M Chronowski; Wenli Dong; G Brandon Gunn; David I Rosenthal; Randal S Weber Journal: Ann Surg Oncol Date: 2014-12-18 Impact factor: 5.344
Authors: Laura S Sasportas; Drew N Hosford; Maria A Sodini; Dale J Waters; Elizabeth A Zambricki; Joëlle K Barral; Edward E Graves; Todd J Brinton; Paul G Yock; Quynh-Thu Le; Davud Sirjani Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2013-05-03
Authors: Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-03-01 Impact factor: 6.223
Authors: Jed J Jacobson; Joel B Epstein; Frederick C Eichmiller; Teresa B Gibson; Ginger S Carls; Emily Vogtmann; Shaohung Wang; Barbara Murphy Journal: Head Neck Oncol Date: 2012-04-26
Authors: Waleed F Mourad; Dukagjin M Blakaj; Rafi Kabarriti; Rebekah Young; Rania A Shourbaji; Jonathan Glanzman; Shyamal Patel; Ravindra Yaparpalvi; Shalom Kalnicki; Madhur K Garg Journal: Case Rep Oncol Med Date: 2013-06-13